Adams Q3
This article was originally published in The Tan Sheet
Executive Summary
Adams Respiratory Therapeutics will institute a 4% price increase for its Mucinex franchise effective July 1, the firm announces during a third-quarter earnings call May 11. Strong market penetration by the brand drove sales for the quarter up 29% to $76 mil., with the entire brand contributing $74.8 mil., the company reports. Net sales of single-ingredient Mucinex (600 mg guaifenesin) grew 20% to $51.9 mil. and sales of Mucinex DM (600 mg guaifenesin/30 mg dextromethorphan) rose 28% to $18.3 mil. Mucinex D (600 mg guaifenesin/60 mg pseudoephedrine), which launched in late October 2005, recorded net sales of $4.7 mil. Adams will allot $50 mil. in ad spend to support a new line of Mucinex pediatric products that are expected to launch in 2006. Separately, the firm will add 25 new representatives to its existing 100-person field force; the new employees are expected to be hired, trained and deployed by July 15...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.